# EDGAR Filing Document

**Accession Number:** 0001948079
**File Stem:** 0001948079-23-000001
**Filing Date:** 2023-1
**Character Count:** 8192
**Document Hash:** 59643d5d21f860c3964f104a592a8ba7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001948079-23-000001.hdr.sgml**: 20230106

**ACCESSION NUMBER**: 0001948079-23-000001

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230104

**FILED AS OF DATE**: 20230106

**DATE AS OF CHANGE**: 20230106

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Soane David
- **CENTRAL INDEX KEY:** 0001948079

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41403
- **FILM NUMBER:** 23514425

**MAIL ADDRESS:**
- **STREET 1:** C/O SOANE LABS, LLC
- **STREET 2:** 380 NE 72ND TERRACE
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33138
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Comera Life Sciences Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001907685
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 12 GILL STREET
- **STREET 2:** SUITE 4650
- **CITY:** WOBURN
- **STATE:** MA
- **ZIP:** 01801
- **BUSINESS PHONE:** 617.871.2101 EXT 313

**MAIL ADDRESS:**
- **STREET 1:** 12 GILL STREET
- **STREET 2:** SUITE 4650
- **CITY:** WOBURN
- **STATE:** MA
- **ZIP:** 01801

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Soane David<br><sub>(Last) (First) (Middle)</sub><br>C/O SOANE LABS, LLC<br>380 NE 72ND TERRACE<br><sub>(Street)</sub><br>MIAMI, FL 33138<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-01-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Comera Life Sciences Holdings, Inc. [ CMRA ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-01-04 |  | P |  | 67567 | A | $1.23 | 3336562<sup>(1)</sup> | I | By Trust<sup>(2)</sup> |
| Common Stock | 2023-01-04 |  | P |  | 67567 | A | $1.23 | 88729<sup>(3)</sup> | I | By Trust<sup>(4)</sup> |
| Common Stock | 2023-01-04 |  | P |  | 67567 | A | $1.23 | 88729<sup>(3)</sup> | I | By Trust<sup>(5)</sup> |
| Common Stock |  |  |  |  |  |  |  | 589786<sup>(6)</sup> | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Warrant (right to buy) | $1.23 | 2023-01-04 |  | P |  | 135134 |  | 2023-01-04 | 2028-01-04 | Common Stock | 135134 | $0.125 | 135134 | I | By Trust<sup>(2)</sup> |
| Warrant (right to buy) | $1.23 | 2023-01-04 |  | P |  | 135134 |  | 2023-01-04 | 2028-01-04 | Common Stock | 135134 | $0.125 | 135134 | I | By Trust<sup>(4)</sup> |
| Warrant (right to buy) | $1.23 | 2023-01-04 |  | P |  | 135134 |  | 2023-01-04 | 2028-01-04 | Common Stock | 135134 | $0.125 | 135134 | I | By Trust<sup>(5)</sup> |

---

### Footnotes:

(1) Includes 663,288 Earn-Out Shares. Earn-Out Shares are shares of Common Stock held in escrow, which shares will be released if, at any time prior to May 19, 2024, either (i) the volume-weighted average price of the Common Stock is equal to or greater than $12.50 for twenty trading days within a thirty trading day period or (ii) upon a change of control with aggregate consideration in excess of $12.50 per share of Common Stock.

(2) Held by The Soane Family Trust, of which David Soane is a trustee and members of the Dr. Soane's immediate family are trustees and beneficiaries. Dr. Soane disclaims beneficial ownership except to the extent of his pecuniary interest therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purposes

(3) Includes 4,298 Earn-Out Shares

(4) Held by the Alexander V. Soane 2019 Irrevocable Trust. Members of David Soane's immediate family serve as trustee and are beneficiaries of such trusts. The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purposes

(5) Held by the Nicholas V. Soane 2019 Irrevocable Trust. Members of David Soane's immediate family serve as trustee and are beneficiaries of such trusts. The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purposes

(6) Includes 119,779 Earn-Out Shares

**Signature:** David S. Soane (individually)  
**Date:** 2023-01-06

**Signature:** David S. Soane, as trustee of the Soane Family Trust  
**Date:** 2023-01-06

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**